News and Trends 15 Jan 2018 This is Why You Should Avoid Eating too Much Junk Food Following last week’s article about the importance of eating plenty of fruit and vegetables, German researchers have unearthed another link between junk food and diabetes and heart disease. Researchers from the University of Bonn, Germany, have found that an unhealthy diet can cause the immune system to act as if it is responding to bacterial […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […] December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Dec 2017 Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017 As 2016 was a tough year for biotech, 2017 was under pressure to turn things around. Although there has been an improvement, there were some notable speed bumps for the industry. 2017 started brightly, with 14 FDA approvals by April – a big improvement on 2016, which only saw 22 in the whole year. The […] December 12, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […] December 4, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Swiss Biotech Rakes in Biggest Fundraising of 2017 to Regenerate Heart Valves Xeltis has raised a €45M Series C to boost the development of its pioneering medical device, RestoreX, which helps to replace damaged heart valves. Xeltis, based in Zurich, Switzerland, is a clinical-stage medical device company developing heart valves and blood vessels to allow the body to naturally restore heart valve function. The biotech has achieved a €45M […] November 15, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it’s Too Late GlyCardial Diagnostics believes it has the technology to prevent premature myocardial infarctions, 80% of which are preventable. Barcelona-based GlyCardial Diagnostics is a biotech, which spun-out from the Catalan Institute of Cardiovascular Science. The startup focuses on the development of an in vitro diagnostic device for myocardial ischemia, which is based on the detection of Apo J-Glyc in the […] November 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […] November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 New Dutch Spin Out will Treat Stroke with RNA Therapy ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […] September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 23 Aug 2017 Dutch Biotech could treat Dyslipidemia with Belgian Nanobody Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and reduce cardiovascular mortality and backed by BioGeneration Ventures and Forbion Capital Partners as investors. Back […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 FREE White Paper! All You need to Know about Omics and Body Fat What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […] July 19, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017 Novartis Scores Major Phase III Win with New Cardiovascular Drug Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that could yield the company a new blockbuster. Now, the Swiss drug maker announced that its cardiovascular drug, canakinumab, was able to meet its primary endpoint in […] June 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2017 Spanish Biotech Clears €2.7M Funding Round for its New Stroke Drug AptaTargets has closed a €2.7M funding round, allowing the biotech to move into the clinic with its first drug candidate for acute ischemic stroke. AptaTargets, located in Madrid, is developing new therapeutic applications based on aptamers. The company is currently focussing on a single lead candidate for the treatment of the acute phase of ischemic […] May 18, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email